Doximity (DOCS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.29
- Estimate
- $0.30
- Surprise
- -4.2%
- Revenue (period 2026-06-30)
- $156.6M
- Score at report (before → after)
- 5.9 → 5.9/10
Revenue source: xbrl.
How the report landed
Doximity (DOCS) missed the $0.30 estimate with adjusted EPS of $0.29 — a clear 4.2% shortfall. TrendMatrix's engine moved from Hold (5.9/10) to Sell at 5.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates DOCS Buy (Wait) at 5.2/10.
2 of the last 4 quarters beat the estimate; this quarter's -4.2% surprise compares with a +2.4% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Weak growth
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $32.74
- Entry target
- $28.17
- Stop
- $26.69
The stock trades at 38.7× trailing but 21.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
DOCS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $5.86B
- P/E (fwd)
- 21.1
- P/E (ttm)
- 38.7
- 52-week range
- $17.15–$67.10
- Off 52-week high
- 51.2%
- RSI (14)
- 67
- Volume vs avg
- 0.16×
- Score today
- 5.2/10